Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.FDA fast-tracks Alto Neuroscience’s ALTO-101 for CIAS treatment
Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with
Currently, there are no approved treatments for CIAS, a key feature of the condition that significantly affects daily functioning and the quality of life for individuals living with
The oral treatment was approved for use on those who continue to experience symptoms despite receiving H1 antihistamine therapy. Rhapsido is administered in pill form twice daily and
The companies will collaborate on the development of GLIX1 as a potential treatment for both newly diagnosed and recurrent GBM. This molecule functions by enhancing TET2 activity within
The submission draws on findings from the TEMPO clinical development programme, which assessed the tolerability, efficacy, and safety of tavapadon in various populations with Parkinson’s disease. This programme
The approval applies to individuals with confirmed amyloid pathology who are apolipoprotein E (ApoE4) heterozygotes or non-carriers. Kisunla, administered as a monthly infusion, is already available in several
The launch follows approval from the US Food and Drug Administration (FDA). Iron sucrose is a key treatment for iron deficiency anaemia, affecting around five million people in
The drug is indicated for adults with mild cognitive impairment or mild dementia, who are non-carriers or heterozygotes of apolipoprotein E ε4 (ApoE ε4) with confirmed amyloid pathology.
The total capital raised by the company now stands at $446m, following a $386m series A/A-1 financing announced in November 2024. The series B round was led by
Phase II study of BW-40202, a small interfering RNA (siRNA) therapy targeting complement factor B (CFB), is planned to commence in January 2026. The therapy is also being
The company aims to achieve early clinical proof-of-concept for the therapy by late 2026. Dewpoint noted that the financing will also expedite the development of its first-in-class c-mod